Investment

down-icon
image
Invest in the world’s largest market with US Stocks

Features

down-icon
support-icon
Pro Tools for Pro Traders
Uncover the powerful trading features

Pro Features

icon
support-icon
Built for Investors
Experience investing with simplified features

Pockets

icon

Fees

Safety

Academy

down-icon

More

down-icon
support-icon
Support

About Us

arrow-icon

Pluang+

|

assetIcon

Allakos Inc (ALLK) Stock Price Today

Overview

Financial

Technicals

Analysis

Corporate Action

About

About Allakos Inc

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.


Technical Indicators

|

|

|

Overall Summary

Bearish (17)

Neutral (8)

Bullish (2)


Performance

ALLK ROI

arrow
-78.4%

% from 52W High

-83.28%
$0.54

52W Low: $0.54

18 Sep 2024

52W High: $3.23

09 Jan 2024


News

Pluang News
Pluang News

Globe Newswire

6mo

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results



People Also Bought

Pluang
Pluang
NKLA
Nikola Corp
-1.62%

US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions



Let’s trade or invest in this asset by signing up or logging in!

register_card

Let’s trade or invest in this asset by signing up or logging in!

You can also download our app!

item